Lista de obras - Francisca Ferrer-Marín - Dominio Público Uruguay

An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.

artículo científico publicado en 2015

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

artículo científico publicado en 2016

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

artículo científico publicado en 2011

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

artículo científico publicado en 2014

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

artículo científico publicado en 2017

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.

artículo científico publicado en 2013

Correction of anaemia on dialysis: did we forget physiology?

artículo científico publicado en 2011

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

artículo científico publicado en 2020

Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes

artículo científico publicado en 2011

Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice

artículo científico publicado en 2013

Effects of in vitro adult platelet transfusions on neonatal hemostasis

artículo científico publicado en 2011

Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 in GNB3.

artículo científico publicado en 2015

Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites.

artículo científico publicado en 2014

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

artículo científico publicado en 2015

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response

artículo científico publicado en 2016

Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia

artículo científico publicado en 2017

Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.

artículo científico publicado en 2015

Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?

artículo científico publicado en 2010

Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.

artículo científico publicado en 2014

Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors.

artículo científico publicado en 2012

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.

artículo científico publicado en 2013

Long-term results of prednisone treatment for the anemia of myelofibrosis.

artículo científico publicado en 2015

Neonatal thrombocytopenia and megakaryocytopoiesis

artículo científico publicado en 2010

Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

scientific article published on 27 May 2016

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

artículo científico publicado en 2015

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

artículo científico publicado en 2016

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.

artículo científico publicado en 2015

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

artículo científico publicado en 2016

Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia

artículo científico publicado en 2020

Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies

artículo científico publicado en 2015

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

artículo científico publicado en 2014

The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.

artículo científico publicado en 2014

[Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms].

artículo científico publicado en 2015

Lista de obras de Francisca Ferrer-Marín

An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.

Correction of anaemia on dialysis: did we forget physiology?

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes

Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice

Effects of in vitro adult platelet transfusions on neonatal hemostasis

Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 in GNB3.

Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites.

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response

Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia

Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.

Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?

Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.

Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors.

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.

Long-term results of prednisone treatment for the anemia of myelofibrosis.

Neonatal thrombocytopenia and megakaryocytopoiesis

Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia

Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.

[Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms].